A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nano-Suspension for Injection Administered Intravenously to Subjects With Solid Tumors.

Trial Profile

A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nano-Suspension for Injection Administered Intravenously to Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2014

At a glance

  • Drugs Ubidecarenone (Primary)
  • Indications Leukaemia; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Berg Pharma
  • Most Recent Events

    • 09 Aug 2013 According to the media release, patients with leukaemia will also be included in this trial.
    • 09 Aug 2013 Status changed from suspended to completed, as reported by a Berg media release.
    • 30 Jul 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top